Date: 2014-03-25
Type of information:
Compound: mitochondrial medicine
Company: NeuroVive Pharmaceutical (Sweden) A1M Pharma (Sweden)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: * On March 25, 2014, NeuroVive Pharmaceutical and A1M Pharma have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a collaboration agreement signed on 21 March 2014. Initially, the purpose of the collaboration is to utilize the companies’ complementary scientific platforms within the framework of ongoing research projects. The companies will evaluate results achieved to date, then explore the potential for a closer collaboration focusing on bringing products to market in a time-efficient manner.The costs related to the research collaboration will be covered by each company separately and within budgeted development projects. Both companies will retain exclusive ownership rights to existing registered intellectual property. However, any inventions arising from the collaboration will be jointly owned by NeuroVive and A1M Pharma.A1M Pharma was incorporated in 2008 with its main focus on the development and commercialization of diagnostics and treatment of pre-eclampsia. Pharmaceuticals development is based on A1M, a protein that protects the body from toxic substances formed in oxidative stress, and repairs damaged tissue. In 2013, the company decided to complement its research to include pharmaceuticals development focusing on renal failure, as recently completed studies indicate that A1M protects renal tissue.NeuroVive Pharmaceutical is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases.
Financial terms:
Latest news:
